Karen M Basen-Engquist1, Margaret Raber2, Cindy L Carmack2,3, Banu Arun4, Abenaa M Brewster5, Michelle Fingeret2, Susan M Schembre2,6, Carol Harrison2, Heidi Y Perkins7, Yisheng Li8, Jaejoon Song8, Minxing Chen8, James L Murray4. 1. Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Unit 1330, P.O. Box 301439, Houston, TX, 77230-1439, USA. kbasenen@mdanderson.org. 2. Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Unit 1330, P.O. Box 301439, Houston, TX, 77230-1439, USA. 3. Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Family and Community Medicine, University of Arizona-College of Medicine, Tucson, AZ, USA. 7. Department of Kinesiology, Rice University, Houston, TX, USA. 8. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
PURPOSE: Weight gain is common among breast cancer patients and may contribute to poorer treatment outcomes. Most programs target breast cancer survivors after the completion of therapy and focus on weight reduction. This study examined the feasibility and preliminary efficacy of an intervention designed to prevent primary weight gain among women receiving neoadjuvant chemotherapy for breast cancer. METHODS: Thirty-eight newly diagnosed stage II or III breast cancer patients were randomized to the BALANCE intervention or usual care within 3 weeks of starting neoadjuvant chemotherapy. The intervention used a size acceptance-based approach and encouraged home-based resistance and moderate-intensity aerobic exercise as well as a low energy-dense diet to prevent weight gain. Assessments were conducted at baseline, mid-chemotherapy (3 months), and post-chemotherapy (6 months). Intervention feasibility, acceptability, and preliminary effects on anthropometric, quality of life, and circulating biomarker measures were evaluated. RESULTS: Intervention participant retention (100%) and in-person session attendance (80%) were high during the intervention period, although attendance dropped to 43% for telephone-delivered sessions. The majority of participants reported being satisfied with the intervention during chemotherapy (88%). Participants in the intervention group had greater reductions in waist circumference (p = .03) and greater improvements in self-reported vitality scores (p = .03) than the control group at the end of chemotherapy. Significant effects on biomarkers were not observed. CONCLUSIONS: A size acceptance weight management program is feasible during neoadjuvant chemotherapy among breast cancer patients and may have beneficial effects on waist circumference and patient vitality. TRIAL REGISTRATION: This study was registered as a clinical trial at www.clinicaltrials.gov (NCT00533338).
PURPOSE: Weight gain is common among breast cancer patients and may contribute to poorer treatment outcomes. Most programs target breast cancer survivors after the completion of therapy and focus on weight reduction. This study examined the feasibility and preliminary efficacy of an intervention designed to prevent primary weight gain among women receiving neoadjuvant chemotherapy for breast cancer. METHODS: Thirty-eight newly diagnosed stage II or III breast cancer patients were randomized to the BALANCE intervention or usual care within 3 weeks of starting neoadjuvant chemotherapy. The intervention used a size acceptance-based approach and encouraged home-based resistance and moderate-intensity aerobic exercise as well as a low energy-dense diet to prevent weight gain. Assessments were conducted at baseline, mid-chemotherapy (3 months), and post-chemotherapy (6 months). Intervention feasibility, acceptability, and preliminary effects on anthropometric, quality of life, and circulating biomarker measures were evaluated. RESULTS: Intervention participant retention (100%) and in-person session attendance (80%) were high during the intervention period, although attendance dropped to 43% for telephone-delivered sessions. The majority of participants reported being satisfied with the intervention during chemotherapy (88%). Participants in the intervention group had greater reductions in waist circumference (p = .03) and greater improvements in self-reported vitality scores (p = .03) than the control group at the end of chemotherapy. Significant effects on biomarkers were not observed. CONCLUSIONS: A size acceptance weight management program is feasible during neoadjuvant chemotherapy among breast cancer patients and may have beneficial effects on waist circumference and patient vitality. TRIAL REGISTRATION: This study was registered as a clinical trial at www.clinicaltrials.gov (NCT00533338).
Entities:
Keywords:
Breast cancer; Obesity; Size acceptance; Survivorship; Weight management
Authors: Ciarán Haberlin; Tom O'Dwyer; David Mockler; Jonathan Moran; Dearbhaile M O'Donnell; Julie Broderick Journal: Support Care Cancer Date: 2018-06-16 Impact factor: 3.603
Authors: W Demark-Wahnefried; V Hars; M R Conaway; K Havlin; B K Rimer; G McElveen; E P Winer Journal: Am J Clin Nutr Date: 1997-05 Impact factor: 7.045
Authors: M M G A van den Berg; R M Winkels; J Th C M de Kruif; H W M van Laarhoven; M Visser; J H M de Vries; Y C de Vries; E Kampman Journal: BMC Cancer Date: 2017-04-12 Impact factor: 4.430
Authors: Rieneke T Lugtenberg; Stefanie de Groot; Ad A Kaptein; Maarten J Fischer; Elma Meershoek-Klein Kranenbarg; Marjolijn Duijm-de Carpentier; Danielle Cohen; Hiltje de Graaf; Joan B Heijns; Johanneke E A Portielje; Agnes J van de Wouw; Alex L T Imholz; Lonneke W Kessels; Suzan Vrijaldenhoven; Arnold Baars; Marta Fiocco; Jacobus J M van der Hoeven; Hans Gelderblom; Valter D Longo; Hanno Pijl; Judith R Kroep Journal: Breast Cancer Res Treat Date: 2020-11-11 Impact factor: 4.872